US OptionsDetailed Quotes

NVS240920P70000

Watchlist

0.00
0.000.00%

15min DelayClose Aug 16 09:30 ET

0.00High0.00Low

Novartis AG Stock Discussion

Arrayfunction

Aug 14 04:37

Talk about a blow to revenue! Shame how sick people don't have infinite money eh?

$Novartis AG (NVS.US)$
On Monday, a Delaware court denied the Swiss pharma giant's attempt for a preliminary injunction to block MSN Pharmaceuticals from launching their generic version on the U.S. market. 2024 guidance doesn't currently account for any generic releases of its best-selling drug Entresto in the U.S., the analysts say. "Should a generic Entresto get to the U.S. market, it would put about 1.5 billion U...

Options Newsman

Jul 15 03:48

Columns Options Volatility: Navigating Big Banks, Healthcare, and Tech Earnings

The earnings season is picking up speed, and this mid-July, we're about to get updates from some of the biggest names across various industries. Expect to hear from large banks, healthcare companies, airlines, and some of the tech and telecom giants that we all know.
The season started off last Friday with $JPMorgan (JPM.US)$ , $Wells Fargo & Co (WFC.US)$ , and $Wells Fargo & Co (WFC.US)$ sharing their numbers. They all did bett...

Meltyy

Jun 14 01:35

🚨 M&A Update! 🚨

Keep an eye on these recently announced M&As: 👀
$Merck & Co (MRK.US)$ to acquire EyeBio
$Biogen (BIIB.US)$ to acquire HI-Bio™
$Johnson & Johnson (JNJ.US)$ to acquire Proteologix
OnKure, Inc. merger with $Reneo Pharmaceuticals (RPHM.US)$
$Novartis AG (NVS.US)$ to acquire Mariana Oncology
What companies will be next? 🤔

life is a blessing

May 29 00:29

Esperion Therapeutics Is Now A Top Choice Takeover Target

$Esperion Therapeutics (ESPR.US)$ Multiple sources indicate that Esperion's advancements and commercial success with its cholesterol-lowering drugs, NEXLIZET and NEXLETOL, have positioned it as defininte acquistion target for larger pharmaceutical companies. Esperion's drugs NEXLIZET and NEXLETOL now have primary prevention labels, NEXLIZET will soon become the drug of choice over a PCSK9 inhibitor says Texas based HeartPlace leading Cardio...

BullnBearTrading

Mar 17 22:23

What Happened Last Trade Day (Mar 15)

Stories you might have missed
Singapore’s private home sales down nearly half in February; 149 condos sold amid holiday lull
DEVELOPERS in Singapore sold 149 private homes in February, 47 per cent fewer than the 281 units moved in January, data released on Friday (Mar 15) by the Urban Redevelopment Authority showed.
Novartis invests US$256 million to expand Singapore plant
SWISS biopharma giant Novartis has invested US$256 million to expand its biopharm...

Moomoo AI

Jan 31 04:28

Google's disappointing ad sales growth and AMD's lower revenue guidance have hurt investor sentiment, causing their shares to drop. Byron Allen's offer to acquire Paramount Global is seen as beneficial for shareholders, boosting its share price. Novartis AG's lower Q4 earnings and adjusted mid-term guidance have led to a share price decline.

Biggest Stock Movers Today: Paramount Global, Google Parent Alphabet, and More

Moomoo AI

Jan 30 07:49

JPMorgan analysts predict a strong uptake for Novartis's various treatments to boost the company's top line, with cost savings from restructuring aiding the bottom line. Morgan Stanley analysts note Novartis's need for external innovation to meet long-term growth ambitions.

Novartis Net Profit Expected to Rise With Outlook in Focus -- Earnings Preview

Meltyy

Jan 18 21:03

M&A Update

Recent M&A activities💰 in January:
$Ambrx Biopharma (AMAM.US)$ acquisition by $Johnson & Johnson (JNJ.US)$
Aiolos Bio acquisition by $GlaxoSmithKline (GSK.US)$
$Harpoon Therapeutics (HARP.US)$ acquisition by $Merck & Co (MRK.US)$
Calypso Biotech acquisition by $Novartis AG (NVS.US)$
What companies will be next? 🤔

Moomoo News Global

Jan 9 05:25

Columns Biotech M&A Frenzy: Is the Industry Poised for a Promising Recovery in 2024?

Since last October, the biotech sector has been showing signs of recovery. This trend was underscored by the S&P Biotechnology Select Industry Index, which surged by 4.69% yesterday and jumped to a new high since Aug 2022.On 8 Jan, J&J, Merck, and Novartis each announced a series of acquisition deals, many of which featured premiums of over 100%:
● $Johnson & Johnson (JNJ.US)$ has agreed to pay $2 billion in cash for antib...

Moomoo Recap US

Jan 8 15:06

Columns Wall Street Today | Boeing Fails to Bring Down Market

RECAP
The $Dow Jones Industrial Average (.DJI.US)$ rebounded after pulling out of a Boeing slump. Indexes opened cautious, but built towards a rebound after the S&P 500 shed 1.5% last week to break a two-month winning streak.
$Dow Jones Industrial Average (.DJI.US)$ climbed 0.58%, the $S&P 500 Index (.SPX.US)$ rose 1.41%, and the $Nasdaq Composite Index (.IXIC.US)$ climbed 2.20%. Large tech stocks led the way; all "Magnificent Seven" stocks were...

Boeing shares fall after CEO admits error

No comment yet